| Autor: |
Hayakawa, Kayoko, Marchaim, Dror, Martin, Emily T., Tiwari, Namita, Yousuf, Adnan, Sunkara, Bharath, Pulluru, Harish, Kotra, Harikrishna, Hasan, Asma, Bheemreddy, Suchitha, Sheth, Puja, Lee, Dae-Won, Kamatam, Srinivasa, Bathina, Pradeep, Nanjireddy, Priyanka, Chalana, Indu K., Patel, Satyam, Kumar, Sarwan, Vahia, Amit, Ku, Kimberly, Yee, Victoria, Swan, Jessie, Pogue, Jason M., Lephart, Paul R., Rybak, Michael J., Kaye, Keith S. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; February 2012, Vol. 56 Issue: 5 p2452-2458, 7p |
| Abstrakt: |
ABSTRACTIn published studies, cohorts of patients with bacteremia due to vancomycin-resistant Enterococcus(VRE) have predominantly been infected with Enterococcus faecium. Little is known about the epidemiology and outcomes associated with bacteremia due to VR Enterococcus faecalis. A retrospective study of isolates obtained from January 2008 to October 2010 was conducted at Detroit Medical Center (DMC). Unique patients with blood cultures positive for VRE were reviewed. Outcomes were analyzed using logistic regression. During the study period, 105 cases of bacteremia due to VR E. faecalisand 197 cases of bacteremia due to VR E. faeciumwere identified. The mean age in the study cohort was 61.5 ± 15 years; 162 subjects (53.6%) were male. After controlling for a propensity score, bacteremia due to VR E. faecaliswas associated with >2-fold-lower in-hospital mortality than bacteremia due to VR E. faecium. Interestingly, bacteremia due to VR E. faecaliswas associated with longer hospital stay after VRE isolation, although total length of stay was similar for groups with VR E. faecalisand VR E. faecium. Bacteremia due to VR E. faecaliswas associated with a >2-fold-lower risk for mortality than bacteremia due to VR E. faecium, possibly due to the availability of β-lactam therapeutics for treatment of VR E. faecalis. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
